A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas

Trial Profile

A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Indoximod (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 28 Jul 2017 According to a NewLink Genetics Corporation media release, the company expects to present updated phase II data from the study at an oncology meeting in late 2017 or early 2018.
    • 04 May 2017 According to a NewLink Genetics Corporation media release, data from this study will be presented at an medical meeting in the second half of 2017
    • 17 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top